Clinical Trial News and Research

RSS

Nymox awarded federal grant for NX-1207 Phase III BPH clinical trial program

Nymox Pharmaceutical Corporation announced today that it has been awarded a grant of $244,479.25 from the U.S Government under the Qualifying Therapeutic Discovery Project for its ongoing Phase III clinical trial program for NX-1207 for the treatment of benign prostatic hyperplasia (BPH). The grant was the maximum allowable for an individual development program.

4 Nov 2010

BioSpecifics receives $426,000 grant under QTDP Program

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that it has received $426,000 in grant funding under the Qualifying Therapeutic Discovery Project (QTDP) Program. The program, funded through the US Patient Protection and Affordable Care Act of 2010, supports therapeutic discovery programs.

4 Nov 2010

PolyMedix receives $488,958 grants under QTDP program

PolyMedix, Inc. a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, announced today that it has been awarded two cash grants totaling $488,958 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

4 Nov 2010

Pharma in Asia-Pacific region becomes more active in R&D, study finds

In recent years, pharmaceutical companies in the Asia-Pacific region have ramped up their clinical trial activity, patent challenges of brand name drugs and their development of new products, according to report released Tuesday by CMR International, a Thomson Reuters business, Reuters reports.

4 Nov 2010

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2010, and company highlights.

4 Nov 2010

BioClinica third quarter service revenues increase to $15.8 million

BioClinica®, Inc., a global provider of clinical trial management services, today announced its financial results for the three and nine months ended September 30, 2010.

From Clario 3 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

QLT third quarter sales decreases 12.9% to $20.5 million

QLT Inc. today reported financial results for the third quarter ended September 30, 2010. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.

3 Nov 2010

New primary care models needed to improve care and outcomes for older adults

In an article published in November 3 edition of Journal of the American Medical Association (JAMA), Chad Boult, MD, MPH, MBA, professor of Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health, calls for key improvements to primary care in order to improve the health of the nation's most costly patients-older adults with multiple chronic conditions.

3 Nov 2010

Incyte announces achievement of $50 million in INCB18424 clinical trial

Incyte Corporation announced today the achievement of $50 million in milestones as part of the Incyte-Novartis collaboration and license agreement for INCB18424.

3 Nov 2010

Fall prevention tool kit effectively reduces falls of older patients in hospitals

Use of a fall prevention tool kit, which included a fall risk assessment, patient-specific prevention plan, an educational handout and a poster for over the patient's hospital bed reduced the number of older patients with falls in hospitals, according to a study in the November 3 issue of JAMA, a theme issue on aging.

3 Nov 2010

Retina Implant's microchip restores useful vision in patients blind due to retinitis pigmentosa

Retina Implant AG, a leading developer of subretinal implants for the visually impaired, today announced the publication of a peer-reviewed study in Proceedings of the Royal Society B discussing the technical and clinical results obtained during their first human clinical trial.

3 Nov 2010

Exact Sciences awarded $244,500 federal grant to develop Cologuard sDNA screening test

Exact Sciences Corp. today announced it has been awarded a $244,500 therapeutic discovery grant from the Internal Revenue Service to aid the company in its development of CologuardTM, an sDNA screening test aimed at detecting both colorectal cancers and pre-cancers.

3 Nov 2010

DARA awarded $0.5M grant under Patient Protection and Affordable Care Act for advancing KRN5500 and DB959

DARA BioSciences announced today grant approvals by the Internal Revenue Service under the Patient Protection and Affordable Care Act of 2010 for KRN5500 and DB959 in the amount of approximately $500,000 for the calendar year 2009.

3 Nov 2010

Pharma companies in Asia Pacific shift to high-risk, high-return research and development

Pharmaceutical companies in the Asia Pacific region are increasingly adapting their business models from the production of generic drugs towards more high-risk, high-return research and development, according to a new report released today by CMR International, a Thomson Reuters business.

3 Nov 2010

BioCancell reports results of BC-819 Phase I/IIa clinical trial for pancreatic cancer

Tikcro Technologies Ltd. today announced that BioCancell reported results from a Phase I/IIa clinical trial to establish the safety, optimal dose and preliminary efficacy of BioCancell's lead drug-candidate, BC-819, as a treatment for pancreatic cancer.

3 Nov 2010

FDA grants Cadence marketing approval for OFIRMEV injection in management of pain and fever

Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for OFIRMEV™ (acetaminophen) injection, the first and only intravenous (IV) formulation of acetaminophen to be approved in the United States. OFIRMEV is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever.

3 Nov 2010

Endologix implants Ventana stent graft for endovascular repair at Auckland City Hospital

Endologix, Inc. developer of minimally invasive treatments for aortic disorders, announced today the first clinical implant of the Company's Ventana fenestrated stent graft at Auckland City Hospital in Auckland, New Zealand.

3 Nov 2010

NeurogesX initiates NGX-1998 Phase 2 study in postherpetic neuralgia

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced dosing of the first patient in its Phase 2 clinical study of NGX-1998, a liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN).

3 Nov 2010

Atrium completes enrollment in iCAST Atrium Registry Ultrasound Study

Atrium Medical Corporation is pleased to announce that the final patient was recently enrolled in the iCAST™ Atrium Registry Ultrasound Study (iCARUS). This study is a prospective, multi-center clinical trial studying the safety and efficacy of the Atrium iCAST™ Balloon Expandable Covered Stent in patients with occlusive disease of the iliac artery.

2 Nov 2010

Clinical Trial News and Research

Nymox awarded federal grant for NX-1207 Phase III BPH clinical trial program

BioSpecifics receives $426,000 grant under QTDP Program

PolyMedix receives $488,958 grants under QTDP program

Pharma in Asia-Pacific region becomes more active in R&D, study finds

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

BioClinica third quarter service revenues increase to $15.8 million

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

QLT third quarter sales decreases 12.9% to $20.5 million

New primary care models needed to improve care and outcomes for older adults

Incyte announces achievement of $50 million in INCB18424 clinical trial

Fall prevention tool kit effectively reduces falls of older patients in hospitals

Retina Implant's microchip restores useful vision in patients blind due to retinitis pigmentosa

Exact Sciences awarded $244,500 federal grant to develop Cologuard sDNA screening test

DARA awarded $0.5M grant under Patient Protection and Affordable Care Act for advancing KRN5500 and DB959

Pharma companies in Asia Pacific shift to high-risk, high-return research and development

BioCancell reports results of BC-819 Phase I/IIa clinical trial for pancreatic cancer

FDA grants Cadence marketing approval for OFIRMEV injection in management of pain and fever

Endologix implants Ventana stent graft for endovascular repair at Auckland City Hospital

NeurogesX initiates NGX-1998 Phase 2 study in postherpetic neuralgia

Atrium completes enrollment in iCAST Atrium Registry Ultrasound Study

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer